Loading...
XTAE
NVLG
Market cap202mUSD
Apr 10, Last price  
147.40ILS
1D
3.08%
1Q
-23.23%
IPO
-11.89%
Name

Novolog Pharm Up 1966 Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
45.82
EPS
—
Div Yield, %
3.99%
Shrs. gr., 5y
7.86%
Rev. gr., 5y
12.52%
Revenues
2.02b
+23.01%
542,786,000629,007,000683,303,000739,219,000839,837,000911,239,0001,004,138,0001,133,643,0001,255,248,0001,507,949,0001,643,489,0002,021,602,000
Net income
40m
P
14,788,00023,539,00025,257,00029,121,00022,492,00021,861,00010,137,00040,067,00042,318,00047,510,000-42,003,00039,538,000
CFO
159m
-20.75%
-55,793,000160,595,000140,292,00020,283,00086,372,00023,963,000101,454,00058,485,00083,387,000132,648,000200,013,000158,517,000
Dividend
Sep 03, 20242.93687 ILS/sh

Profile

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.
URL
https://www.novolog.co.il/
IPO date
Feb 28, 2017
Employees
926
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,021,602
23.01%
1,643,489
8.99%
1,507,949
20.13%
Cost of revenue
1,860,746
1,593,017
1,348,391
Unusual Expense (Income)
NOPBT
160,856
50,472
159,558
NOPBT Margin
7.96%
3.07%
10.58%
Operating Taxes
16,688
10,474
17,128
Tax Rate
10.37%
20.75%
10.73%
NOPAT
144,168
39,998
142,430
Net income
39,538
-194.13%
(42,003)
-188.41%
47,510
12.27%
Dividends
(40,000)
(16,900)
(31,900)
Dividend yield
4.40%
2.33%
2.23%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
21,311
27,517
23,210
Long-term debt
375,635
401,859
400,220
Deferred revenue
Other long-term liabilities
2,590
19,979
9,016
Net debt
149,348
180,240
208,317
Cash flow
Cash from operating activities
158,517
200,013
132,648
CAPEX
(13,394)
(70,955)
(69,490)
Cash from investing activities
(50,548)
(72,603)
(124,948)
Cash from financing activities
(94,590)
(67,712)
(72,959)
FCF
189,823
55,073
75,039
Balance
Cash
247,598
232,939
172,806
Long term investments
16,197
42,307
Excess cash
146,518
166,962
139,716
Stockholders' equity
18,875
51,053
120,782
Invested Capital
564,331
580,228
556,538
ROIC
25.19%
7.04%
26.78%
ROCE
26.98%
8.00%
22.96%
EV
Common stock shares outstanding
510,739
510,922
515,793
Price
1.78
25.33%
1.42
-48.70%
2.77
-6.70%
Market cap
909,626
25.29%
726,020
-49.18%
1,428,747
-6.57%
EV
1,072,742
931,301
1,663,116
EBITDA
239,512
166,013
212,412
EV/EBITDA
4.48
5.61
7.83
Interest
12,608
12,868
12,537
Interest/NOPBT
7.84%
25.50%
7.86%